[EN] 5-MEMBERED AND BICYCLIC HETEROCYCLIC AMIDES AS INHIBITORS OF ROCK<br/>[FR] AMIDES HÉTÉROCYCLIQUES À 5 CHAÎNONS ET BICYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE ROCK
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2019014308A1
公开(公告)日:2019-01-17
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.
A compound of the formula (I):
1
wherein R
1
is hydrogen or lower alkyl;
R
2
is lower alkyl, etc.;
R
3
is lower alkoxy, etc.;
R
4
is hydroxy, etc.;
X is O, S, etc.;
Y is CH or N;
Z is lower alkylene or lower alkenylene; and
m is 0 or 1; or salts thereof, which are useful as a medicament.
[EN] IMIDAZOLE AND TRIAZOLE DERIVATIVES USEFUL AS SELECTIVE COX-1 INHIBITORS<br/>[FR] DERIVES D'IMIDAZOLE ET DE TRIAZOLE UTILES EN TANT QU'INHIBITEURS DE COX-1 SELECTIFS
申请人:FUJISAWA PHARMACEUTICAL CO
公开号:WO2004060367A1
公开(公告)日:2004-07-22
A compound of the formula (I): or salts thereof, which are useful for treatment and/or prevention of inflammatory conditions, various pains, collagen diseases, autoimmune diseases, thrombosis, cancer or neurodengenerative diseases.
[EN] NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER<br/>[FR] NOUVELLES COMPOSITIONS ET PROCÉDÉS POUR TRAITER LE CANCER
申请人:UNIV TEXAS
公开号:WO2013063492A1
公开(公告)日:2013-05-02
Provided herein are methods and compositions inter alia for treating diseases, including hyperproliferative diseases, migraine headaches, and depression.
本文提供了用于治疗疾病的方法和组合物,包括治疗过度增殖性疾病、偏头痛和抑郁症等。
TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
申请人:Genentech, Inc.
公开号:US20180065983A1
公开(公告)日:2018-03-08
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure:
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.